Health officials in China have confirmed a case of bubonic plague in a herdsman from the Inner Mongolia district, triggering increased prevention measures throughout the region.
Editor-in-Chief Jason Gallagher PharmD, FCCP, FIDP, FIDSA, BCPS discusses this agent as a potential tool for preexposure prophylaxis (PrEP) against HIV infection. And if it is approved, the ability to overcome access issues in low to middle income countries that have a greater need.
In 2017, lower respiratory tract infections linked with influenza were responsible for an estimated 145,000 deaths worldwide.
We review current and emerging treatment options for infections caused by the difficult-to-treat, intrinsically multidrug-resistant organism Stenotrophomonas maltophilia.
This virus has multiple facets and highlights a need for real-time learning.
“A bite bug in the belly.”
Despite having emerged as either the third or fourth leading cause of blood stream infections in the United States, the threat of multi-drug resistant Candida species remains an underappreciated concern.
Parallels between the recent Zika epidemic in Brazil and the HIV pandemic in the 1980s, stress the importance of improving responses to public health crises.
This is a challenging pathogen, requiring pharmacokinetic and pharmacodynamic considerations; the recent FDA approval of sulbactam-durlobactam offers new hope.
Government agencies and researchers continue to monitor the potentially troubling trend.
A survey of 571 US hospitals regarding practices used to prevent Clostridium difficile infection indicates that nearly half of the facilities appear to not be taking steps to prevent the infection that kills nearly 30,000 people and sickens hundreds of thousands more each year, despite strong evidence that these steps work.
The quick Pitt Bacteremia Score offers accuracy comparable to the original version's across multiple infections, and maintains ease of use.
Quick recognition is key to early initiation of treatment and long-term survival.
Clinicians review a patient case including diagnosis, treatment, and follow-up.
The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.
Two recently approved agents offer significant activity against these hard-to-treat conditions.
New agents are in development, but none represent a magic bullet for the problems that CRE infections present.
The phase 3 study met its primary and secondary end points of all-cause mortality, microbiological eradication rates, and new Staphylococcus aureus bacteremia complications.
Two recently approved agents offer significant activity against these hard-to-treat conditions.
Infectious diseases clinicians turn to Twitter as a tool for education and collaboration.
Growing evidence suggests that antimicrobials also interact with host innate immunity to provide potent indirect effects which enhance bacterial clearance and may result in more rapid and complete effects
A novel study from Seddon and colleagues adds to the body of evidence that supports what antimicrobial stewardship programs are so often challenged to do, early de-escalation.
Use of an IL-6 inhibitor has the potential to prevent the cytokine storm caused by severe COVID-19 infection.
Studies have shown high rates of inappropriate antibiotic prescribing and opportunity for improvement when it comes to ABSSSIs.
Differences in the clinical presentations of ZIKV infection which are occurring in different parts of the world might be an obstacle to setting a case definition that is good for use in all areas.
Advances in antiretroviral therapies increase opportunities for patients with HIV to have more successful treatment outcomes.
Despite the initial abandonment of bacteriophages in most areas of the world, the era of antibiotic resistance has led to a resurgence of phage therapy in clinical practice.
Despite the initial abandonment of bacteriophages in most areas of the world, the era of antibiotic resistance has led to a resurgence of phage therapy in clinical practice.
The clinical characteristics and outcomes of Pneumocystis jirovecii pneumonia differ in immunocompromised patients with and without HIV.
The vaccine reduced the risk of herpes zoster by 68.2% in high-risk recipients of hematopoietic stem cell transplant.